Chronic Obstructive Pulmonary Disease, Quality of Life, COPD Assessment Test, Nepal, Dyspnea, Spirometry

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. The study "Quality of life among people living with Chronic Obstructive Pulmonary Disease- visiting spirometry center of Tribhuvan University Teaching Hospital, Kathmandu Nepal" aims to assess the quality of life (QOL) of COPD patients and the factors affecting it.

A cross sectional study will be performed among the patients visiting Spirometry center of Tribhuvan University Teaching Hospital, Kathmandu Nepal using Convenience Sampling. Ethical approval will be obtained from Institutional Review Board (IRB) of TUTH and written/verbal consent for data collection will be obtained from Teaching hospital authority as well as the respondents. CAT questionnaire will be used to assess quality of life and the Medical Research Council questionnaire will be used to assess the severity of dyspnea. Data management and analysis will be conducted through Statistical Package for Social Sciences (SPSS) version 26.0.

Study Overview

• Status: Not yet recruiting
• Conditions: Quality of Life; COPD (Chronic Obstructive Pulmonary Disease)
• Intervention / Treatment: Other: Evaluation of Quality of life in COPD patients

• Study Type: Observational
• Enrollment (Estimated): 71

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study enrolled participants aged 20 years or older who were referred to the spirometry center of Tribhuvan University Teaching Hospital. The primary inclusion criterion was a confirmed diagnosis of COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, defined as a postbronchodilator ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) < 0.70.

Description

Inclusion Criteria:

• Age ≥ 20 years
• Referred to the spirometry center of Tribhuvan University Teaching Hospital
• Confirmed diagnosis of COPD based on GOLD criteria: post-bronchodilator FEV1/FVC < 0.7

Exclusion Criteria:

• Unable to perform acceptable spirometry maneuvers
• Presence of significant respiratory diseases that can confound COPD assessment (e.g., asthma, bronchiectasis, active tuberculosis)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Health-Related Quality of Life (HRQoL) Score (COPD Assessment Test - CAT)	The COPD Assessment Test (CAT) score ranges from 0 to 40, with 0 indicating no impact and 40 indicating the worst impact on quality of life. Higher scores represent worse outcomes.	1 month

Collaborators and Investigators

• Sponsor: Institute of medicine, Maharagjung medical campus

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: November 14, 2025
• First Submitted That Met QC Criteria: November 28, 2025
• First Posted (Estimated): December 3, 2025

Study Record Updates

• Last Update Posted (Estimated): December 3, 2025
• Last Update Submitted That Met QC Criteria: November 28, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 353 (6-11) E2 077/ 078

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Since this is an observational study focused on evaluating the quality of life of COPD patients, Individual Participant Data (IPD) will not be shared as part of the study's results. However, the aggregated findings, such as overall satisfaction scores and analysis of demographic factors influencing consent understanding, will be presented in the final study report.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No